Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Moran T, Palmero R, Provencio M, Insa A, Majem M, Reguart N, Bosch-Barrera J, Isla D, Costa EC, Lee C, Puig M, Kraemer S, Schnell D, Rosell R. Moran T, et al. Among authors: reguart n. Lung Cancer. 2017 Jun;108:154-160. doi: 10.1016/j.lungcan.2017.03.009. Epub 2017 Mar 22. Lung Cancer. 2017. PMID: 28625629 Clinical Trial.
Molecular predictors of response to chemotherapy in lung cancer.
Rosell R, Taron M, Ariza A, Barnadas A, Mate JL, Reguart N, Margel M, Felip E, Méndez P, García-Campelo R. Rosell R, et al. Among authors: reguart n. Semin Oncol. 2004 Feb;31(1 Suppl 1):20-7. doi: 10.1053/j.seminoncol.2003.12.011. Semin Oncol. 2004. PMID: 14981577 Review.
Integrating concurrent navelbine and cisplatin to hyperfractionated radiotherapy in locally advanced non-small cell lung cancer patients treated with induction and consolidation chemotherapy: feasibility and activity results.
Reguart N, Viñolas N, Casas F, Gimferrer JM, Agustí C, Molina R, Martin-Richard M, Sanchez-Reyes A, Gascón P. Reguart N, et al. Lung Cancer. 2004 Jul;45(1):67-75. doi: 10.1016/j.lungcan.2003.12.012. Lung Cancer. 2004. PMID: 15196736 Clinical Trial.
The promise of pharmacogenomics: gemcitabine and pemetrexed.
Rosell R, Taron M, Sanchez JM, Moran T, Reguart N, Besse B, Isla D, Massuti B, Alberola V, Sanchez JJ. Rosell R, et al. Among authors: reguart n. Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):70-6. Oncology (Williston Park). 2004. PMID: 15655942 Free article. Review.
Wnt signaling in stem cells and non-small-cell lung cancer.
He B, Barg RN, You L, Xu Z, Reguart N, Mikami I, Batra S, Rosell R, Jablons DM. He B, et al. Among authors: reguart n. Clin Lung Cancer. 2005 Jul;7(1):54-60. doi: 10.3816/CLC.2005.n.022. Clin Lung Cancer. 2005. PMID: 16098245 Review.
156 results